Anti-PD-1 predominantly leads to the proliferation of exhausted-like CD8+ T cells within the tumor, whereas CTLA-4 inhibitor mainly results in the amplification of CD4+ effector cells and exhausted-like CD8+ T cells 19. The gene discussed is CD8A; the disease is neoplasm.